Just quickly, I wanted to say something about the auto sector, because my colleague asked about it. The 2012 study commissioned by Foreign Affairs, Trade and Development Canada said that for the Canadian automotive sector a Canada-EU CETA would lead to a 0.16% decline in automobile production, and presumably those very integrated supply chains would be impacted.
My question is actually in regard to my colleague's last point about the cost of drugs. Twenty-five per cent of Bill C-30 is changes to patents. At this point, unfortunately, we have no IP witnesses scheduled to come before the committee on such a significant change. I believe the generics companies say that this is the most significant change in over 20 years in Canada.
Picking up on her point about what we can do to address this, you mentioned pharmacare and bulk buying, but I wonder if you could speak to the implications that CETA could have for the ability of Canada to bring in some form of pharmacare or bulk buying.